Diabetes technology

Swimming With the Omnipod 5 Automated Insulin Delivery System: An Observational Investigation of Swimmers With Type 1 Diabetes in the Omnipod 5 Pivotal Trial

Diabetes Obes MetabPublished Observational study

Authors' conclusion

Swimming with AID was associated with generally modest declines in glucose. The Omnipod 5 System largely preserved automation in water (often via Automated Mode: Limited) without reverting to Manual Mode. Starting glucose dominated glycemic trajectory, with larger declines but low hypoglycemia risk at a higher starting glucose, and smaller changes, but more hypoglycemia at a lower starting glucose. Insulin suspension was not enough to reliably prevent hypoglycemia when starting glucose was < 180 mg/dL, highlighting the need for proactive carbohydrate intake with a lower starting glucose, even with AID.

Study context

Population
Swimmers with T1D using the Omnipod 5 Automated Insulin Delivery (AID) System (aged 11 ± 2 years, 57% female), Omnipod 5 pivotal trial124 swims
Participants
7 participants
Outcome
Glycemic patterns and system operation during swimming
Follow-up
During swims
Methodological detailsSwims recorded with an activity tracker; online surveys after swims
  • Swims recorded with an activity tracker; online surveys after swims

Main finding

As reported in the abstract

Starting glucose, median (IQR)

133 (93-178) mg/dL

Glucose change during swims, median (IQR)

−17 (−61 to 7) mg/dL

Swim time in Automated Mode

98%

95%–100%

Share of that time in Automated Mode: Limited

58%

24%–70%

Observational data: associations, not effects.

Further findings

Glucose change during swims with starting glucose ≥ 181 mg/dL

Largest glucose decreases
−86 (−111 to −25) mg/dL

Carbohydrate intake 2-h before swims

Carbohydrate intake
20 (0-32) grams

Activity feature use in swims with starting glucose < 90 mg/dL

Activity feature used
87%

Original publication

Swimming With the Omnipod 5 Automated Insulin Delivery System: An Observational Investigation of Swimmers With Type 1 Diabetes in the Omnipod 5 Pivotal Trial. Diabetes Obes Metab. Published 30 March 2026. doi:10.1111/dom.70715

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.